24results about "Mammal lectins" patented technology

Disclosed herein are anti-Galectin-9 antibodies and methods of using in modulating (e.g., increasing) immune responses in a subject, either taken alone or in combination with an immune checkpoint inhibitor, such as a PD-1 inhibitor.

The invention relates to the technical field of aquatic animal immune regulation and control, in particular to rHoLL-like stepped lectin-like recombinant protein as well as a preparation method and application thereof. The recombinant protein has pathogen-related molecular pattern recognition and combination capabilities, can promote aggregation of pathogens in a body fluid environment, and activates an aquatic animal complement system, so that the non-specific immune defense capability is enhanced. The preparation method comprises the following steps: amplifying a HoLL-like mature peptide coding sequence, constructing a recombinant expression vector, and converting the recombinant expression vector into an escherichia coli expression host for induced expression to obtain rHoLL-like lectin-like recombinant protein existing in an inclusion body form; and carrying out affinity chromatography purification on the inclusion body protein, and carrying out renaturation treatment in a manner of gradient reduction of denaturant concentration to obtain the rHoLL-like stepped lectin-like recombinant protein. The rHoLL-like stepped lectin-like recombinant protein has good biological safety, and can be applied to aquaculture as an aquatic animal immunopotentiator or a related biological product.

The disclosure is in the field of immunology and oncology, especially for treating, preventing, or inhibiting proliferative diseases, particularly cancer, infectious diseases and disorders associated with dysfunction of TNF cytokines. The disclosure relates to a novel SPD-TNFSF fusion protein including a TNF-superfamily (TNFSF) ligand, or receptor binding domain thereof, fused to a coiled-coil domain of surfactant protein-D (SPD). Also provided a trimeric or multimeric fusion protein including a plurality of SPD-TNFSF fusion proteins. The disclosure also provides an expression vector as mRNA, plasmid or virus including an isolated nucleotide sequence encoding the SPD-TNFSF fusion protein and a cell or a pharmaceutical composition including thereof.

The present invention relates to a lectin for use in the treatment, reduction in progression and curing of inflammation in a subject in need thereof. Pharmaceutical compositions comprising said lectin are also described. The lectin may comprise an amino acid sequence having sequence of SEQ ID NO: 1 or at least 60% homology to SEQ ID NO: 1.

The present invention relates to fusion proteins which interact with and regulate the activation and / or the activity of the complement system. Preferably the fusion protein comprises a pattern recognition molecule (PRM) or a fragment thereof and a complement control protein (CCP) or a fragment thereof.

Described herein are Galectin-1 / Galectin-3 multivalent protein complexes and uses thereof. In some aspects, Galectin-1 / Galectin-3 multivalent protein complexes are useful to treat inflammatory conditions in a subject.

Provided is a fusion construct that includes (1) a glycan-targeting domain capable of specifically binding a pre-determined sugar molecule (such as one over-expressed on certain cancer cell surface), (2) an aggregating domain capable of self-aggregation to form multimers among molecules containing the same domain, and (3) an optional solubilizing domain, which is connected to (1) or (2) via a peptide linker optionally containing a protease (such as one over-expressed on certain cancer cell surface) cleavage site. Also provided is using of said construct in treatment of cancer.

The present invention relates to a process for preparing a recombinant lectin having the amino acid sequence of SEQ ID NO: 1, wherein the process comprises fed-batch fermentation of a clone in a host cell at a carbon to nitrogen ratio of 3:1 to 6:1 and at a specific feed rate. The present invention also relates to a purification process for the recombinant lectin having the amino acid sequence of SEQ ID NO: 1.

Disclosed herein is a CLEC2 fusion protein comprising a first polypeptide and a second polypeptide coupled to the upstream of the first polypeptide. According to embodiments of the present disclosure, the first and the second polypeptides respectively comprise the amino acid sequences of SEQ ID NOs: 1 and 2. Also disclosed therein are uses of the CLEC2 fusion protein in treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and treating influenza virus infection.

The invention provides compositions and methods for treating, reducing or preventing cytokine storm, for example, in connection with a viral infection (e.g., by SARS-CoV-2), drug treatment or therapy, trauma or an inflammatory disease, or a related disease and disorder.

Provided herein, inter alia, are variant lectin anti-viral polypeptides as well as compositions and methods for expressing and using the same for the treatment and prevention of viral disease in animals.

The present invention relates to a bifunctional peptide comprising a virus binding moiety (2) and a mucin binding moiety (1) covalently bound to the virus binding moiety (2). The virus binding moiety is chosen from peptides binding to SARS-CoV-2, to influenza A, to influenza B, to rhinoviruses and other enteroviruses, to human parainfluenza virus, and / or to metapneuvirus. The mucin binding moiety is chosen from lectins such as trefoil factor 3.

The present invention relates to a humanized animal model incorporating a retinoschisis gene variant found in human patients and, specifically, to a humanized animal model carrying a c.422G>A (p.R141H) variant identified in the RS1 gene of human patients with retinoschisis, a use thereof, and the like.

The present disclosure is generally related to methods and compositions for producing heterologous lectin proteins of interest in recombinant filamentous fungal cells. Certain embodiments are therefore, directed to compositions and methods for the production of lectin proteins, recombinant filamentous fungal strains comprising enhanced lectin protein productivity phenotypes, polynucleotides (e.g., expression constructs) encoding one or more lectin proteins, industrial scale fermentation, lectin protein recovery processes and the like.

A diversity-generating system comprising: a polynucleotide comprising: a variable region within a sequence encoding a protein or polypeptide, wherein the system is configured to generate a library of diversified molecules with an efficiency of 80% as measured by number of the diversified molecules in total number of molecules. The system may further comprise a template region; and a reverse transcriptase or functional domain thereof.

Disclosed herein are methods and compositions for preventing or inhibiting amyloid complex formation of proteins that form pathological aggregates. Examples of these proteins include α-synuclein, tau protein, TDP-43, transthyretin, uromodulin, islet amyloid polypeptide (IAPP), serum amyloid A (SAA), p53, apolipoprotein E (APOE), APOE-4, prion protein, fibrin, or neurofilament light (NFL), CRP, SUMO, light chain, platelet-derived growth factor receptor (PDGFR), melanoma cell adhesion molecule (MCAM), complement proteins C3 and / or C9, lysozyme, insulin, native haemoglobin (Hb), glycosylated haemoglobin (HbAIC), phenylalanine (Phe), glutamine (Gln), cholesteryl (co-esteryl), cholesterol, neuroserpin, Crystallin AA and / or Crystallin AB, cystatin-C, and myostatin propeptide. These methods and compositions involve antibodies or binding fragments thereof that bind to galectin-3 (Gal3).

The present application relates to a pharmaceutical composition for preventing or treating bone diseases, comprising a recombinant galectin-9 protein, and in particular, to a pharmaceutical composition for preventing or treating bone diseases including rheumatoid arthritis, comprising a recombinant galectin-9 protein in which amino acids of a linker peptide are deleted and amino acids of a C-terminal domain (CCRD) are deleted and substituted, as an effective ingredient.

The present disclosure provides a trefoil factor 2 (TFF2) / interferon α2 (IFNα2) fusion protein and an application thereof in prevention and treatment of viral infectious diseases. Specifically, the present disclosure provides a fusion protein, comprising: a TFF2 element containing a TFF2 peptide, and an IFNα2 element fused with the TFF2 element and containing an IFNα2 peptide. The present disclosure also provides an application of the fusion protein in prevention and / or treatment of viral infectious diseases (e.g., acute respiratory / enterovirus infections).

The present disclosure provides a trefoil factor 2 (TFF2) / interferon α2 (IFNα2) fusion protein and an application thereof in prevention and treatment of viral infectious diseases. Specifically, the present disclosure provides a fusion protein, comprising: a TFF2 element containing a TFF2 peptide, and an IFNα2 element fused with the TFF2 element and containing an IFNα2 peptide. The present disclosure also provides an application of the fusion protein in prevention and / or treatment of viral infectious diseases (e.g., acute respiratory / enterovirus infections).

The present invention provides novel substances that are useful for the preventive treatment of viral diseases, and ideally, for avoiding viral infections. The bifunctional peptide of the present invention has a virus-binding site 2 and a mucin-binding site 1 covalently linked to the virus-binding site 2. The virus-binding site 2 is selected from peptides that bind to SARS-CoV-2, influenza A, influenza B, rhinovirus, or other enteroviruses, human parainfluenza viruses, and / or metaneuviruses. The mucin-binding site 1 is selected from lectins such as trefoil factor 3.

The present invention discloses a lamprey serum globular lectin, a preparation method thereof and its application in the detection of liver cancer, belonging to the technical field of cancer detection. The present invention discovers that glycosylation modification is abnormally highly expressed in liver cancer patients. The lamprey serum globular lectin is isolated and purified from lamprey serum. The lamprey serum globular lectin can specifically bind to glycan structures such as Galβ1-3GlcNAc, GlcNAcβ1-2Man and Manα1-2Man of glycoproteins in liver cancer tissues, and can be used for the diagnosis of liver cancer. The lamprey serum globular lectin of the present invention can diagnose liver cancer efficiently and specifically, is particularly sensitive to the diagnosis of intrahepatic cholangiocarcinoma, has high reference value for the diagnosis of liver cancer, and is suitable for popularization and application.

The present invention relates to the use of compounds that reduce signalling pathways induced by CLEC-1 / TRIM21 interaction, in particular compounds that antagonise the interaction, in particular the binding between CLEC-1 and TRIM21, the use of the identified ligand TRIM21 in identifying cells suspected of interacting with cells expressing CLEC-1, for designing treatments in patients and their use in therapy.

The present disclosure relates generally to methods and compositions for the production of heterologous lectin proteins of interest in recombinant filamentous fungal cells. Thus, certain embodiments relate to compositions and methods for producing lectin proteins, including recombinant filamentous fungal strains that include lectin protein productivity enhancing phenotypes, polynucleotides (e.g., expression constructs) encoding one or more lectin proteins, industrial scale fermentation, lectin protein recovery processes, and the like.